RNA splicing is a key regulatory step in the proper control of gene expression. It is a highly dynamic process orchestrated by the spliceosome, a macro-molecular machinery that consists of protein and RNA components. The dysregulation of RNA splicing has been observed in many human pathologies ranging from neurodegenerative diseases to cancer. The recent identification of recurrent mutations in the core components of the spliceosome in hematologic malignancies has advanced our knowledge of how splicing alterations contribute to disease pathogenesis. This review article will discuss our current understanding of how aberrant RNA splicing regulation drives tumor initiation and progression. We will also review current therapeutic modalities and highlight emerging technologies designed to target RNA splicing for cancer treatment.
CITATION STYLE
Bonner, E. A., & Lee, S. C. (2023, July 1). Therapeutic Targeting of RNA Splicing in Cancer. Genes. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/genes14071378
Mendeley helps you to discover research relevant for your work.